Industry Briefs: Apr. 2, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Albany Molecular Research has agreed to license to Bessor Pharma its tubulin-inhibitor program for treating cancer. Read More
A federal district court has ruled in favor of AstraZeneca on its formulation patent for Seroquel (quetiapine fumarate) extended-release tablets. Read More
BioStorage Technologies has expanded its services in the academic research sector throughout the northeast United States. Read More
Eisai and Minophagen Pharmaceutical have concluded a license agreement concerning the development and commercialization of the cutaneous T-cell lymphoma treatment bexarotene. Read More
Gerresheimer has acquired Neutral Glass. Read More
GlaxoSmithKline has agreed to purchase 10 million shares to increase its ownership in Theravance. Read More
Illumina’s board of directors has unanimously rejected Roche’s revised offer to acquire the company for $51 per share in cash. Read More
Pharmaceutical Research and Manufacturers of America has issued a statement to support the National Governor’s Association’s Prescription Drug Abuse Reduction Policy Academy. Read More
Sigma Aldrich has acquired Research Organics. Read More
People News
Laureate Biopharma has named Lisa Cozza as vice-president of business development. Read More
Merck has appointed Michael J. Holston as chief ethics and compliance officer, effective June 25, 2012. He will succeed Richard S. Bowles, who plans to retire from the company. Read More
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
